nach oben

Erschienen in:

26.01.2021 | Oncology

Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma

verfasst von: Toshiki Terao, Youichi Machida, Kentaro Narita, Ayumi Kuzume, Rikako Tabata, Takafumi Tsushima, Daisuke Miura, Masami Takeuchi, Ukihide Tateishi, Kosei Matsue

Erschienen in: European Radiology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study compared the tumor burden and prognostic impact of total diffusion volume (tDV) and total lesion glycolysis (TLG) in the same patients with newly diagnosed multiple myeloma (NDMM) simultaneously. We also examined the relationship between these imaging tumor volumes (TVs) and plasma cell (PC) TV in bone marrow (BM) specimens.

Methods

We retrospectively reviewed the data of 63 patients with newly diagnosed multiple myeloma (NDMM) from April 2016 to March 2018. tDV was calculated from whole-body diffusion-weighted imaging and TLG was calculated from the average standard uptake value and the metabolic tumor volume, respectively. Cellularity of BM hematopoietic tissue and the percentage of BM PCs were used as a reference of PC volume in the BM.

Results

The Spearman correlation coefficient between tDV and TLG was moderate (ɤs = 0.588, p < 0.001) when PET false-negative patients were excluded. There were positive correlations between the BM plasma cell volume (BMPCV) and the imaging TVs (ɤs = 0.505, vs. tDV; and 0.464, vs. TLG). Patients with high tDV and high TLG, as determined by the receiver operating characteristic curve, had worse survival; moreover, patients with both high tDV and high TLG showed the worst prognosis (median progression-free and overall survival: 13.2 and 28.9 months, respectively).

Conclusions

Although tDV and TLG each reflected the total TV, in several cases, tDV and TLG were discrepant due to the biological features of each MM. It is important to use both modalities for complementary assessment of total tumor burden and biological characteristics in MM.

Key Points

• Total diffusion volume (tDV) and total lesion glycolysis (TLG) reflect the total tumor volume and have prognostic value in patients with multiple myeloma (MM).

• tDV and TLG could assess MM from different biological perspectives and should be considered for each patient individually.

Nur mit Berechtigung zugänglich

Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548CrossRef

Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346CrossRef

Nonomura Y, Yasumoto M, Yoshimura R et al (2001) Relationship between bone marrow cellularity and apparent diffusion coefficient. J Magn Reson Imaging 13:757–760CrossRef

Hillengass J, Bauerle T, Bartl R et al (2011) Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 153:721–728CrossRef

Dimopoulos MA, Hillengass J, Usmani S et al (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 33:657–664CrossRef

Cavo M, Terpos E, Nanni C et al (2017) Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206–e217CrossRef

Hillengass J, Usmani S, Rajkumar SV et al (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302–e312CrossRef

Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 291:5–13CrossRef

Tsujikawa T, Oikawa H, Tasaki T et al (2019) Whole-body bone marrow DWI correlates with age, anemia, and hematopoietic activity. Eur J Radiol 118:223–230CrossRef

10.

Lecouvet FE, Vande Berg BC, Michaux L et al (1998) Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 209:653–660CrossRef

11.

Walker R, Barlogie B, Haessler J et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121–1128CrossRef

12.

Moulopoulos LA, Dimopoulos MA, Kastritis E et al (2012) Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol 87:861–864CrossRef

13.

Haznedar R, Aki SZ, Akdemir OU et al (2011) Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 38:1046–1053CrossRef

14.

Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118:5989–5995CrossRef

15.

McDonald JE, Kessler MM, Gardner MW et al (2017) Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res 23:1981–1987CrossRef

16.

Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L (2020) Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol 99:127–135CrossRef

17.

Takasu M, Kondo S, Akiyama Y et al (2020) Assessment of early treatment response on MRI in multiple myeloma: comparative study of whole-body diffusion-weighted and lumbar spinal MRI. PLoS One 15:e0229607CrossRef

18.

Terao T, Machida Y, Tsushima T et al (2020) Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol 191:223–230CrossRef

19.

Fonti R, Larobina M, Del Vecchio S et al (2012) Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med 53:1829–1835CrossRef

20.

Nanni C, Zamagni E, Versari A et al (2016) Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 43:414–421CrossRef

21.

Matsue K, Matsue Y, Kumata K et al (2017) Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry. Hematol Oncol 35:323–328CrossRef

22.

Hirata K, Kobayashi K, Wong KP et al (2014) A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One 9:e105682CrossRef

23.

Dennis E, Hinkle WW, Jurs SG (2003) Applied statistics for the behavioral sciences, 5th edn. Boston’s Houghton Mifflin Harcourt, Boston

24.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRef

25.

Larson SM, Erdi Y, Akhurst T et al (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2:159–171CrossRef

26.

Rasche L, Angtuaco E, McDonald JE et al (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30–34CrossRef

27.

Abe Y, Ikeda S, Kitadate A et al (2019) Low hexokinase-2 expression-associated false-negative (18)F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging 46:1345–1350CrossRef

28.

Cao W, Liang C, Gen Y, Wang C, Zhao C, Sun L (2016) Role of diffusion-weighted imaging for detecting bone marrow infiltration in skull in children with acute lymphoblastic leukemia. Diagn Interv Radiol 22:580–586CrossRef

29.

Mori N, Ota H, Mugikura S et al (2015) Luminal-type breast cancer: correlation of apparent diffusion coefficients with the Ki-67 labeling index. Radiology 274:66–73CrossRef

30.

Onishi N, Kanao S, Kataoka M et al (2015) Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma. J Magn Reson Imaging 41:610–615CrossRef

31.

Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21:1713–1718CrossRef

32.

Albano D, Patti C, Lagalla R, Midiri M, Galia M (2017) Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging 45:1082–1089CrossRef

33.

Rasche L, Chavan SS, Stephens OW et al (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268–278CrossRef

Titel: Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma
verfasst von: Toshiki Terao
Youichi Machida
Kentaro Narita
Ayumi Kuzume
Rikako Tabata
Takafumi Tsushima
Daisuke Miura
Masami Takeuchi
Ukihide Tateishi
Kosei Matsue
Publikationsdatum: 26.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 8/2021
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-021-07687-2

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma